Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0268-0965 vs Insulin Glargine in T2DM
NCT04575181Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2020
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nnc0268-0965 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in flow mediated dilation at 26 weeks. Started Oct 2020; status: completed.
02
Drugs
nnc0268-0965
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04575181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04575181.